$0.99
(Market cap
$6,110 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
8.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-0.2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-35.6
-
Debt to Equity
--
-
Book Value
$--
-
EPS
$-2.8
-
Face value
--
-
Shares outstanding
40,272,144
Years Aggregate
CFO
$--
EBITDA
$--
Net Profit
$--
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Belite Bio Inc ADR (BLTE)
| -2.0 | -1.2 | 8.7 | 148.6 | 65.8 | -- | -- |
|
BSE Sensex*
| -9.8 | -2.2 | 2.8 | -5.0 | 5.3 | 5.9 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
|---|---|---|---|
|
Belite Bio Inc ADR (BLTE)
| 153.5 | 37.6 | 51.8 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Belite Bio Inc ADR (BLTE)
|
156.7 | 6,110.1 | 0.0 | -102.4 | -- | -26.6 | -- | 8.2 |
| 82.7 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 71.4 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 56.9 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 107.7 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 363.8 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 538.7 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 583.2 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 353.4 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 146.5 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout Belite Bio Inc ADR (BLTE)
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally... administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company also develops LBS-009, an retinol binding protein 4 oral therapy, which is in preclinical development targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, as well as gout. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd. Read more
-
Chairman of the Board of Directors & CEO
Dr. Yu-Hsin Lin M.B.A., Ph.D.
-
Chairman of the Board of Directors & CEO
Dr. Yu-Hsin Lin M.B.A., Ph.D.
-
Headquarters
San Diego, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Belite Bio Inc ADR (BLTE)
What is the current share price of Belite Bio Inc ADR (BLTE) Today?
The share price of Belite Bio Inc ADR (BLTE) is $156.70 (NASDAQ) as of 01-Sep-2026 16:00 EDT. Belite Bio Inc ADR (BLTE) has given a return of 65.85% in the last 3 years.
What is the current PB & PE ratio of Belite Bio Inc ADR (BLTE)?
Since, TTM earnings of Belite Bio Inc ADR (BLTE) is negative, P/E ratio is not available.
The P/B ratio of Belite Bio Inc ADR (BLTE) is 8.18 times as on 28-Aug-2026, a 58 premium to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-69.12 |
6.96 |
2024 |
-54.91 |
13.61 |
2023 |
-40.95 |
14.33 |
2022 |
-49.22 |
15.00 |
2021 |
-- |
-- |
What is the 52 Week High and Low of Belite Bio Inc ADR (BLTE)?
The 52-week high and low of Belite Bio Inc ADR (BLTE) are Rs 200.00 and Rs 62.18 as of 02-Sep-2026.
What is the market cap of Belite Bio Inc ADR (BLTE)?
Belite Bio Inc ADR (BLTE) has a market capitalisation of $ 6,110 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Belite Bio Inc ADR (BLTE)?
Before investing in Belite Bio Inc ADR (BLTE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.